Stocks Market
Sothema Reports 12% Revenue Rise in Q1 2026, Boosted by New Products and Dialysis Expansion
Sothema announced a solid 12 % increase in consolidated revenue for the first quarter of 2026, reaching MAD 879 million. The growth was driven by strong performance in strategic therapeutic areas, the integration of Soludia’s dialysis solutions, three new product launches and the acquisition of the CIALIS brand rights. The group also reduced its net debt by 13 % and increased its capital spending dramatically, underscoring a proactive investment strategy.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Quarterly Highlights
In the first three months of fiscal 2026, Sothema generated a consolidated turnover of MAD 879 million, up 12 % year‑on‑year. On a constant‑currency basis the growth is 4 %.
Drivers of Growth
The rise is anchored by strong performance across several strategic therapeutic areas and the integration of Soludia’s dialysis‑solution portfolio, which accelerated the group’s overall expansion.
Product Launches
Sothema introduced three new medicines during the quarter – two in cardiology and one in oncology – reinforcing its position in high‑potential segments.
Regulatory Activity
- 9 marketing‑authorisation (AMM/CE) applications filed, including one dietary supplement.
- 12 approvals granted within the quarter.
Investments and Acquisitions
Capital expenditures climbed to MAD 77 million, a sharp rise from MAD 9 million a year earlier, mainly driven by the purchase of the CIALIS brand rights and associated products from Eli Lilly for the Moroccan market.
Financial Position
Net consolidated debt fell to MAD 725 million at 31 March 2026, down from MAD 833 million at year‑end 2025 – a 13 % reduction.
The consolidation scope remained unchanged during Q1 2026.